Download the Imaging in TAT webinar here:

Targeted Alpha Therapy

Targeted Alpha Therapy (TAT) is gaining significant traction in cancer treatment. The first FDA-approved TAT was Radium-223 in 2013.  Multiple TAT approaches in multiple tumor types1 are being investigated in ongoing clinical trials.

 

In particular, TAT has demonstrated considerable therapeutic efficacy with 225Ac-labeled PSMA-617 in heavily pre-treated as well as chemotherapy-na├»ve advanced prostate cancer patients2,3,4 (see Figure below).

 

 

Who Can I Contact?

Want to learn more about Invicro's Imaging TAT capabilities? Contact Us Here. 

Invicro's preclinical TAT capabilities include:

  • Radiolabeling and functional testing of small and large molecules with alpha emitters
  • TAT biodistribution studies
  • Theranostics: In vivo imaging with surrogate isotopes (e.g. 111In replacing 225Ac in labeled target molecule)
  • TAT efficacy studies: tumor growth (deceleration or remission) compared to control groups, including urinalysis and CBC analysis
  • Radiation dosimetry studies and analysis with candidate or surrogate radionuclides

TAT

Clinical capabilities include:

  • IND drafting and submission for novel imaging biomarkers
  • Phase 0/1 first in human studies for novel imaging biomarkers and radiopharmaceutical therapies
  • Central imaging core lab for Phase 0-4 studies, imaging protocol and image review charter, site selection and training, data management and analysis (expert blinded reads, response assessment, full 21 CFR Part 11 compliance)

 

1Parker C et al. JAMA Oncol. 2018

2Kratochwil et al. JNM 2016

3Kratochwil et al. JNM 2018

4Sathekge et al. EJNMMI 2018

 

 

Who Can I Contact?

Want to learn more about Invicro's Imaging TAT capabilities? Contact Us Here. 

 

TESTIMONIALS

Our Pharma Sponsors

We were very happy with the data we received from the pilot study. I would like to plan a new, bigger study and ask slightly more sophisticated questions.

Great job and great slides. Beautiful images!

......one thing has remained constant as we generate more data, and that is your dedication to quality science.